Basiliximab

Generic Name: Basiliximab

Brand Names: Simulect

Drug Type: Biotech

CAS Number: 179045-86-4

Unique Ingredient Identifier: 9927MT646M

Background: A recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also known as CD25 antigen) on the surface of activated T-lymphocytes. It is a 144 kDa glycoprotein obtained from fermentation of an established mouse myeloma cell line genetically engineered to express plasmids containing the human heavy and light chain constant region genes and mouse heavy and light chain variable region genes encoding the RFT5 antibody that binds selectively to the IL-2R alpha.

Indication: For prophylactic treatment of kidney transplant rejection

Associated Conditions: Rejection Acute Renal

Clinical Trials

Impact of Lymphocyte Anti-metabolite Immunosuppressions on Donor-Specific Anti-HLA Antibody and Kidney Graft Outcome

Phase 4

Completed

Conditions: Kidney Transplant

Interventions: Drug: Mycophenolate mofetil 500mg Tab. or 250mg Cap.
Drug: Tacrolimus
Drug: Methylprednisolone/prednisolone
Drug: Basiliximab

First Posted Date: 2019-01-07

Last Posted Date: 2024-05-22

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 169

Registration Number: NCT03794492

Locations: 🇰🇷
Ajou University Hospital, Suwan, Korea, Republic of

Basiliximab Treating Interstitial Pneumonia of CADM

Phase 2

Conditions: Lung; Disease, Interstitial, With Fibrosis
Dermatomyositis

Interventions: Drug: Basiliximab
Drug: Calcineurin Inhibitors
Drug: Steroids

First Posted Date: 2017-06-20

Last Posted Date: 2017-06-20

Lead Sponsor: RenJi Hospital

Target Recruit Count: 100

Registration Number: NCT03192657

Locations: 🇨🇳
RenJi Hospital, Shanghai, Shanghai, China

Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major

Phase 4

Conditions: Thalassemia Major

Interventions: Drug: Busulfan
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Mycophenolate mofetil
Drug: Tacrolimus
Drug: Methotrexate
Drug: Thymoglobulin
Drug: Basiliximab

First Posted Date: 2017-05-31

Last Posted Date: 2017-05-31

Lead Sponsor: First Affiliated Hospital of Guangxi Medical University

Target Recruit Count: 30

Registration Number: NCT03171831

Locations: 🇨🇳
First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China

Basiliximab vs Low-dose Thymoglobulin Induction Therapy in Low Risk Kidney Transplant Patients

Phase 4

Completed

Conditions: Kidney Transplant; Complications
Kidney Transplant Rejection

Interventions: Drug: Thymoglobulin
Drug: Basiliximab

First Posted Date: 2016-12-30

Last Posted Date: 2019-11-15

Lead Sponsor: Coordinación de Investigación en Salud, Mexico

Target Recruit Count: 100

Registration Number: NCT03006419

Locations: 🇲🇽
Umae Hospital Especialidades 14 Adolfo Ruiz Cortines, Veracruz, Mexico

Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients

Phase 2

Completed

Conditions: Kidney Transplantation
Primary Focal Segmental Glomerulosclerosis (FSGS)

Interventions: Drug: Bleselumab
Drug: Basiliximab
Drug: Mycophenolate Mofetil (MMF)
Drug: Tacrolimus Capsules
Drug: Methylprednisone
Drug: Prednisone

First Posted Date: 2016-10-03

Last Posted Date: 2024-12-04

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 67

Registration Number: NCT02921789

Locations: 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Washington University in St. Louis, Saint Louis, Missouri, United States

and more 20 locations